Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance and Stock Impact - Alexandria Real Estate reported lower-than-expected results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 27-28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property, which was deemed not suitable for life science scaling [5][6].

As filed with the Securities and Exchange Commission on January 16, 2026. Registration No. 333-291993 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ AMENDMENT NO.1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ______________________________ HELIX ACQUISITION CORP. III (Exact name of registrant as specified in its charter) ______________________________ | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdict ...

Core Viewpoint - Merck KGaA is positioning itself for a "next wave of growth" through three strategic pillars: Process Solutions in Life Science, rare diseases in Healthcare, and Semiconductor Solutions in Electronics, while reaffirming its 2025 guidance and outlining expectations for 2026 [4][7][8]. Group 1: Strategic Growth Pillars - The company operates across three main business segments: Healthcare, Life Science, and Electronics, focusing investments on these growth pillars [2][4]. - In Life Science, Merck emphasizes its leadership in bioprocessing within Process Solutions, highlighting strong growth momentum and stable long-term market fundamentals [2][3]. - The acquisition of SpringWorks is seen as a strategic move to bolster the rare diseases segment in Healthcare, which is now considered a new strategic pillar [2][6]. - In Electronics, Semiconductor Solutions accounts for approximately 80% of Electronics sales, positioning the company to benefit from AI-driven demand [5][17]. Group 2: Financial Guidance and Growth Expectations - Management confirmed its 2025 guidance, expecting mid-single-digit organic sales growth for the overall group and low double-digit growth from the three strategic pillars, which are projected to contribute over 80% of future growth [7][10]. - The company anticipates margin expansion of about 100 basis points, although this may be impacted by healthcare lifecycle effects in 2026 [7][10]. Group 3: Life Science Segment Insights - A new organizational design in Life Science was implemented to enhance customer interactions, structured around Process Solutions, Advanced Solutions, and Discovery Solutions [11]. - The Process Solutions segment is expected to be the primary growth engine, targeting around 10% organic growth over the midterm, driven by demand in both traditional and novel modalities [13]. - Near-term challenges are noted in lab-related businesses due to muted conditions in China and cautious purchasing behavior in the U.S. academic sector [13]. Group 4: Healthcare Segment Developments - The loss of exclusivity for Mavenclad in the U.S. presents a near-term headwind, but growth is expected to be driven by the rare disease franchise and fertility products like Pergoveris, which has shown a 20% compound annual growth rate outside the U.S., Japan, and China [6][16]. - Three priority products in the rare disease segment have a combined peak sales potential of approximately EUR 2.5 billion [6][15]. Group 5: Electronics Segment Dynamics - The shift towards advanced nodes in semiconductor solutions is highlighted, with more than 50% of Merck's semiconductor portfolio in advanced nodes compared to 33% in the broader market [5][17]. - Advanced packaging is identified as a significant growth area, with expectations of exceeding EUR 100 million in sales [5][19].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, specifically titled Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust (REIT) with a focus on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance and Stock Impact - Alexandria Real Estate reported lower-than-expected results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 27-28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million related to its Long Island City property, which was deemed not suitable for life science scaling [5][6].

Market Overview - The market is experiencing a rally as the likelihood of a Federal Reserve rate cut increases, with December odds now at 70%, up from 33% [1] - The technology sector is showing positive momentum, supported by stronger earnings trends compared to the overall market [5] Sector Analysis - The healthcare sector is viewed as under-owned and priced for pessimism, having shown healthy earnings trends across various sub-sectors [6] - The technology sector has reset after a significant six-month rally, with some stocks experiencing a 40% decline since October highs [4] Investment Sentiment - There is a belief that the market is not priced for perfection, as some areas have become euphoric, but a reset has occurred [3] - The current market conditions are seen as favorable for continued growth, driven by earnings and advancements in productivity, particularly in AI [13] Future Outlook - The expectation is that the Federal Reserve will cut rates in the coming year, which will support higher earnings and market growth [10][14] - Historical trends suggest that November typically sees a bottom around November 20th, leading into a seasonal rally [11] Volatility and Risks - Recent volatility in stocks and Fed funds futures is noted, but it is suggested that the market will rally into December despite potential concerns [15][16] - The market has shifted expectations for a December rate cut to 80%, which could pose a risk if conditions change unexpectedly [15]

Group Financial Performance and Strategy - Merck aims to drive sustainable value creation as a leading science & technology company[7] - The company is actively managing its portfolio, focusing on attractive markets and solid competitive positions, with >80% of businesses in each category[10, 11] - Merck confirms M&A guardrails and financial discipline, with ongoing scouting for further M&A to accelerate growth[18] - The company is committed to topline growth and margin expansion mid-term[72] - Merck is on track to meet its 2025 guidance and has a positive early indication for 2026, with an expected EBITDA pre margin of ~29% in 2025[69, 70] Key Growth Drivers - Key growth drivers explain up to 80% of future growth, focusing on secular growth markets[20] - Process Solutions market segment continues to grow at a 9% to 10% CAGR[37] - Semiconductor Solutions contribute over 80% to Electronics sales mid-term[50] - Healthcare mid-term growth ambition is raised, driven by Rare Diseases uptake, targeting LSD to MSD organic sales growth (CAGR in %)[46] Life Science Strategy - Life Science is centering the business on three distinct go-to-market approaches: Process Solutions (~€35 billion), Advanced Solutions (~€47 billion), and Discovery Solutions (~€29 billion)[32]

Industry Leadership & Innovation - US is considered the best country for innovation in life sciences [1] - The life science industry in the US is expected to remain the undisputed leader in healthcare innovation [3] - The US possesses key elements for innovation: universities, research institutions, talent, and capital markets [2] Optimism & Resilience - The speaker expresses optimism about the future of the life science industry [3] - The speaker believes things will come through fine despite ups and downs [3] - The speaker references Johnson & Johnson's 140-year history of navigating challenges [3] Addressing Concerns - Some researchers feel under attack from the government [2] - The speaker expresses confidence that these issues will be resolved [3]

Core Insights - Kilroy Realty Corporation has executed a lease for 24,000 square feet at Kilroy Oyster Point Phase 2, a life science development project in South San Francisco [1] Company Developments - The lease agreement with Color signifies the appeal of Kilroy Oyster Point Phase 2 to life science tenants, indicating strong demand in this sector [1] - Occupancy for the new lease is set to commence early next year, reflecting the company's ongoing commitment to expanding its life science portfolio [1]

Company Performance & Outlook - Danaher delivered a strong quarter with healthy revenue beat, steady organic growth, and better-than-expected margins, leading to a $0.16 earnings beat [6] - Management raised their full-year earnings forecast and gave healthy guidance for the current quarter [6] - Investors initially reacted negatively to the earnings report, but the stock rebounded and finished up 1% on Tuesday and continued to rise in the following days [7][10] - The core bioprocessing business is rebounding, supporting high single-digit core growth in the second half [15][16] Challenges & Concerns - China sales were down mid-single digits due to volume-based procurement and reimbursement changes implemented by Chinese authorities [12][13] - Volume-based procurement in China is a result of the national strategy to curb healthcare costs, impacting multiple companies [14] - CFO Matthew Mcgru will be retiring next year [8] Biotechnology Segment Analysis - The biotechnology segment reported better-than-expected results with 8% sales growth and 150 basis points of operating margin expansion [14] - The bioprocessing division, a $6 billion business, is showing positive order trends [15] - Monoclonal antibodies represented over 75% of the bioprocessing unit sales [16] Investment Strategy - The author expresses confidence in Danaher's turnaround and recommends buying the stock [19][21] - The author suggests waiting for United Health's report before making decisions on managed healthcare companies like Sigma [20]

Financial Performance & Guidance - DHC's Q1 2025 total revenues reached $386.9 million[12] - The company reported a net loss of $9 million, equivalent to $0.04 per share[12] - Normalized FFO stood at $14.3 million, or $0.06 per share[12] - DHC anticipates SHOP NOI to range between $120 million and $135 million for 2025[9] - Medical Office and Life Science NOI is projected to be between $104 million and $112 million[9] - Triple Net Leased (NNN) NOI is expected to be in the range of $29 million to $31 million[9] SHOP Initiatives & Performance - SHOP same property NOI increased by 42.1% year-over-year, driven by a 6.5% increase in same property revenue[12] - This revenue growth is attributed to a 110 bps increase in occupancy and a 4.5% increase in average monthly rate[12] - SHOP occupancy grew to between 82% and 83%[12] - SHOP margins are expected to improve by 200 bps to 400 bps[12] Capital Recycling & Dispositions - DHC estimates disposition proceeds of $680 million to $730 million[12] - As of May 16, 2025, $337 million in dispositions had been completed year-to-date[12] - An additional $330 million to $380 million in dispositions are in various stages of marketing, including $110.5 million under agreements or letters of intent[12,33]